Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Non-phase study NCT05425043

Granulocyte Transfusions After Umbilical Cord Blood Transplant

Granulocyte Transfusions After Umbilical Cord Blood Transplant — Active Not Recruiting • Non-phase study • Oncology • NCT05425043.

📅 09 Jun 2026 ⏱ 2 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT05425043
Start
2021-09-14
Completion
2026-06-30
ClinicaliQ Trial Snapshot
  • Granulocyte Transfusions After Umbilical Cord Blood Transplant — Active Not Recruiting • Non-phase study • Oncology • NCT05425043.
  • Study testing whether white blood cell transfusions improve immune recovery and outcomes after cord blood stem cell transplant in children with leukaemia.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Although most children with leukaemia are cured using drugs (chemotherapy) alone, for some children additional treatments are needed. Stem cell transplant can cure children where chemotherapy and other drugs have failed. In this case, the immune cells of the donor attack the leukaemia cells of the patient. Cord blood collected from the placenta of unrelated babies is often used as a donor cell source and appears to work well at controlling leukaemia and less likely to cause complications such as when the immune cells also mistakenly attack healthy tissues (called…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Oncology · 18 Jun 2026
Serplulimab combined with carboplatin and etoposide is recommended as first-line treatment for untreated extensive-stage small-cell lung cancer (ES-SCLC) and should be considered…
View guideline →
Guideline
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
Oncology · 19 Aug 2026
First-line treatment option: Acalabrutinib combined with bendamustine and rituximab is recommended as a first-line treatment for untreated mantle cell lymphoma, offering an…
View guideline →
Guideline
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia
Oncology · 19 Aug 2026
Use acalabrutinib with venetoclax ± obinutuzumab as first-line treatment for untreated CLL – this combination is recommended by NICE and offers improved…
View guideline →
Clinical Brief
BBC News presenter reveals she has blood cancer
Oncology · BBC Health · 06 Sep 2026
High-profile diagnosis raises public awareness of blood cancer, potentially increasing patient consultations and need for GPs to recognise presenting symptoms Media coverage…
View brief →
Clinical Brief
Heart trial after breast cancer has ‘improved my life’
Oncology · BBC Health · 02 Sep 2026
Women completing breast cancer treatment can safely discontinue cardioprotective medications (likely ACE inhibitors/beta-blockers) without adverse cardiac outcomes, based on evidence from a…
View brief →
Guideline
Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)
Oncology · 20 Aug 2026
This NICE evaluation was terminated, meaning lisocabtagene maraleucel is not currently recommended for routine NHS use in relapsed or refractory follicular lymphoma—do…
View guideline →